Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/30/2024 | Outperform → Mkt Perform | William Blair | |
| 3/3/2022 | Outperform → Market Perform | Cowen & Co. | |
| 11/24/2021 | $10.00 → $9.00 | Buy | HC Wainwright & Co. |
EDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr. Levy brings over 20 years of experience at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb, and has a strong track record of leading clinical strategy and development efforts for numerous programs at all stages of development. "We are thrilled to welcome Dr. Levy to our Board of Directors," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "He is a recognized
EDINBURGH, United Kingdom, Aug. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Jeffrey D. Bloss, M.D. as Chief Medical Officer. Dr. Bloss will be based in NuCana's US offices located outside Boston, MA. "We are delighted to welcome Jeff to the executive team at NuCana," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Jeff brings over two decades of experience leading clinical development and medical affairs at several biotechnology and pharmaceutical companies. His achievements include leading the development, approval and
SCHEDULE 13D/A - NuCana plc (0001709626) (Subject)
6-K - NuCana plc (0001709626) (Filer)
6-K - NuCana plc (0001709626) (Filer)
William Blair downgraded NuCana from Outperform to Mkt Perform
Cowen & Co. downgraded NuCana from Outperform to Market Perform
HC Wainwright & Co. reiterated coverage of NuCana with a rating of Buy and set a new price target of $9.00 from $10.00 previously
Experienced Healthcare Executive to Lead Finance Organization Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced today that Donald Munoz is joining the Company as chief financial officer (CFO), reporting to Greg Kunst, chief executive officer (CEO). "We are delighted to welcome Don to our executive team," said Greg Kunst, Aurion's CEO. "Don's track record of strategic and operational financial leadership, coupled with his extensive experience as a healthcare investment banker, make him an ideal addition to Aurion." "I'm thrilled to join Aurion as CFO," said Don Munoz. "I believe that Aurion's l
Presented Encouraging Phase 2 Data on NUC-7738 in Combination with Pembrolizumab at the European Society for Medical Oncology (ESMO) Congress 2024 Announced Promising Phase 1b/2 Data on NUC-3373 in Combination with Pembrolizumab or Docetaxel Anticipated Cash Runway into Q2 2025 EDINBURGH, United Kingdom, Nov. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the third quarter ended September 30, 2024 and provided an update on its clinical development program with its two lead anti-cancer medicines. "We announced encouraging data from our ongoing clinical studies of both NUC-7738 and NUC-3373, underscoring the potential of our pipeline," said Hugh S.
Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Pembrolizumab One Patient Achieved a 100% Reduction in their Target Lesion Patients with Lung Cancer who had Exhausted All Other Treatment Options Achieved Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Docetaxel EDINBURGH, United Kingdom, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced that initial data from the ongoing Phase 1b/2 modular study (NuTide:303) investigating NUC-3373 in combination with the PD-
SC 13G/A - NuCana plc (0001709626) (Subject)
SC 13D/A - NuCana plc (0001709626) (Subject)
SC 13G/A - NuCana plc (0001709626) (Subject)